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One approach to assessing progress against cancer is to examine
changes in the survival of cancer patients over time. Survival data
for patients registered with cancer are compiled centrally by the
Office for National Statistics (ONS) from information collected by
regionally based cancer registries, and these data provide the main
source of routine survival statistics for England and Wales.
Although the ONS data include information on time from diag-
nosis to death, the specific cause of death is not routinely collected
and so conventional estimates of survival based on these data
reflect death from all causes rather than just the cancer of interest.
Corresponding trends in survival estimates are sometimes difficult
to interpret because it may be unclear whether changes in survival
over time among a given group of cancer patients are in fact due to
changes in the risk of death from the cancer itself, or to changes in
the risk of death from causes other than that cancer.
In situations like this, it is common to use some form of ‘relative
survival rate’ (Ederer et al, 1961) which is usually defined as a
measure of survival ‘corrected’ for the effect of other independent
causes of death, commonly referred to as background mortality.
Although this approach appears simple in principle, there has been
considerable debate in the statistical literature as to the correct
choice of estimate, and it has been shown that use of certain esti-
mates can lead to spurious results for long-term relative survival
(Hakulinen, 1977).
This paper aims to provide a straightforward introduction to the
concept of relative survival and reviews some of the suggested
methods for estimation. In particular, a simple person–years
approach is described that is based on directly interpretable
measures such as observed and expected numbers of deaths. This
approach is illustrated using preliminary data from ONS on cancer
survival in patients born after 1939 who were diagnosed with
cancer during the period 1972–84.
Materials and methods
The concept of relative survival was devised to provide an objec-
tive measure of the proportion of patients dying from the direct or
indirect consequence of a disease in a given population and, hence,
a measure of survival corrected for the effect of other independent
causes of death. The basic definition of the relative survival rate is
given below.
Let Td denote the time to death assuming that the subject is only
at risk of death from the disease of interest, Te the time to death
assuming that the subject is only at risk of death from all other
causes, and T=minimum(Td,Te) the observed time to death, all
measured from some suitable reference point such as date of diag-
nosis. Assuming that the cause of interest and all other causes are
independent, the overall probability of surviving to time t is
Pr(T ³ t) = Pr(T d ³ t) Pr(T e ³ t),
hence,
Sr(t) = Pr(Td ³ t) =
Pr(T ³ t)
=
S(t)
Pr(Te ³ t) Se(t) (1)
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where Se(t) denotes the probability of survival to time tif at risk
from all other diseases, and S(t) is the observed probability of
survival to time t. The ratio Sr(t) is termed the relative survival rate
and can be viewed as the probability of survival to time twith the
disease of interest in the absence of the risk of death from other
causes. Unlike crude survival, which would be expected to decline
with increasing time, a levelling off in the relative survival rate
after a given time, t, can occur if the individual is no longer at risk
of death from the disease of interest. Thus, an apparent flattening
of the cumulative relative survival curve is often taken to indicate
that individuals who survive a given length of time are effectively
‘cured’ of the disease.
In general, S(t) is estimated by the observed life–table estimate,
based on the study cohort. The term Se(t) is substituted by some
estimate of the expected probability of survival to time t, from all
causes other than the disease of interest, for a group similar to that
under study. Most of the discussion of the relative survival rate has
centred on the choice of estimate for Se(t). The simplest approach,
adopted by Ederer et al (1961), is to calculate the expected t-year
survival probability for each individual alive at the beginning of
the follow-up, based on relevant available life–tables, and take
Se(t) to be the average of these values; in other words:
Se(t) =
1
N Sj
Se
j(t), (2)
where Nis the total number of individuals in the study cohort. This
estimate of Se(t) depends only on the composition of the cohort at
the beginning of the study and takes no account of the subsequent
withdrawal pattern.
The main problem with the estimate in equation 1, which was
originally identified by Hakulinen (1977), becomes apparent when
long-term relative survival rates are considered. Suppose that we
are interested in the overall relative survival rate for a heteroge-
neous cohort; using equations 1 and 2, this can be expressed as the
following weighted average
Sr(t) =
SjnjSj(t)
=
SjnjSr
j(t) Se
j(t)
=SjwjSr
j(t),
SjnjSe
j(t) SjnjSe
j(t) (3)
where jis taken to denote age group or any other prognostic factor, nj
is the number of individuals in the jth group at the start of the study and
wj =
njSe
j(t)
, j= 1, …, m.
SjnjSe
j(t)
As tbecomes large, wj tends to unity for the group with the best
‘expected survival’, Se
j(t), and to zero for all other groups. Thus, as
the time period of interest increases, the overall relative survival
estimate will tend to that of the group with the best expected
survival, usually the youngest group. If one plots the relative
survival rate (equation 3) for a heterogeneous population as a
function of time, it sometimes appears as if relative survival starts
to increase after a long period of time. Many people have attrib-
uted this to the possibility that improved medical care of cancer
patients prevents them dying of causes other than their primary
disease, but it may well be a spurious effect of using the form
equation 2 as an estimate of Se(t) (Hakulinen, 1977).
If the expected survival of the study group was in itself of
interest, equation 2 would be the correct estimate because it is
based entirely on the composition of the study group at time 0 and
is unaffected by the subsequent withdrawal pattern. However, the
other component in equation 1, the observed survival S(t), is
heavily dependent on the pattern of withdrawal. The estimate of
Se(t) should also, therefore, take into account the changing compo-
sition of the cohort by, for example, replacing Se(t) with a
life–table estimate of expected survival as proposed by Ederer and
Heise (1959). A simpler alternative approach, however, is to use
the notion of excess death rates based on observed and expected
mortality as suggested, for example, by Pocock et al (1982). In
their paper, Pocock et al use excess deaths rates to make valid
comparisons of survival between groups with potentially different
background mortality rates. In what follows, we assume that
interest lies specifically in estimating relative survival and, there-
fore, show how to translate excess or net mortality into corre-
sponding relative survival estimates and derive corresponding
approximate confidence intervals.
For each year (or other suitable time interval) after diagnosis, let
Odenote the observed number of deaths in the study cohort, Ethe
expected number of deaths from causes other than the disease of
interest (based on appropriate regional rates and taking into
account calendar period, age and/or other relevant factors), and Y
the number of person–years contributed during that interval. The
‘net mortality rate’, that is the difference between the observed
Table 15-year relative survival rates for patients diagnosed with cancer 1972–84 by primary site
Cancer (ICD code Age at Total number of Per cent 5-year relative survival rate (95% CI) for
under: 8th revision, diagnosis registrations years of diagnosis
9th revision) (years)
1972–75 1976–78 1979–81 1982–84
Breast cancer
(174, 174) 15–34 5893 57 (55–60) 60 (57–62) 61 (58–63) 62 (59–64)
Testicular cancer
(186, 186) 15–34 5220 65 (62–67) 73 (70–76) 85 (83–87) 89 (87–91)
Hodgkin’s disease
(201, 201) 15–34 6300 76 (74–77) 80 (78–82) 82 (80–84) 87 (85–89)
Acute lymphatic
leukaemia 0–14 3659 45 (42–48) 52 (49–55) 64 (60–67) 74 (70–77)
(204, 204) 15–34 1044 22 (18–28) 30 (25–36) 34 (28–40) 44 (38–50)
Acute myeloid 
leukaemia 0–14 598 9 (6–13) 18 (12–25) 19 (13–26) 34 (25–42)
(205, 205) 15–34 1324 6 (4–8) 14 (10–18) 20 (16–25) 31 (26–36)20 GK Reeves et al
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mortality rate and that which would be expected from all other
causes, in the ith year after diagnosis is simply
li =
(Oi – Ei)
.
Yi
This net death rate is taken to represent the death rate due to the
cause of interest in the ith year. If patients who survive to time t are
no longer at any excess risk of death relative to the general popula-
tion then the net mortality rate at time t should be 0 and this can be
used as a statistical test of ‘curability’. The cumulative t-year net
mortality rate can be expressed as
L(t) = St
1li,
and, hence, the t-year relative survival rate is given by
Sr(t) = e–L(t). (4)
Approximate confidence intervals for the relative survival esti-
mate, Sr(t), can be derived by assuming a normal distribution for
log {–log Sr(t)}, with estimated variance
s2 =
St
1 Oi /Yi
2
{St
1(Oi – Ei)/Y i}2.
Thus, an approximate 95% confidence interval for Sr(t) is given by
Sr(t)exp(±1.96s)
Person–years for each time interval and the corresponding
expected number of deaths can be obtained using any of the
standard algorithms, for example PERSON–YEARS (Coleman et al,
1986), and the remaining calculations are easily programmed.
Several other approaches to the estimation of relative survival
have been proposed (Hakulinen, 1982, 1985), but these are generally
more complex than those described here. The person–years approach
described above can be thought of as a special case of a more gener-
alized modelling approach proposed by Esteve et al (1990) in which
the net mortality rate is allowed to depend on any number of explana-
tory variables. Such a modelling approach is clearly more appropriate
when primary interest lies in assessing which of many potential
factors are important in determining mortality from the cause of
interest. In some situations, it may be of interest to compare survival
in a group of patients with their expected survival given their
observed values of certain relevant covariates. In this case, Thomsen
et al (1991) consider a continuous time analogue of relative survival
in which the component representing expected survival takes into
account historical information about the relationship between
survival and the covariates of interest.
RESULTS
Application of the method to the analysis of survival of
young patients diagnosed with cancer in England and
Wales during 1972–84
The data used here are a subset of the national data on patients with
cancer, compiled by ONS, and are unique in that the vital status of
every patient registered after 1971 has been specially checked against
the National Health Service Central Register. This subset includes
data for only a few cancer sites and is limited to people born after
1939. The examples in this paper are, therefore, limited to results of
analyses on a small number of selected cancers in relatively young
patients, aged under 35 at diagnosis, and diagnosed between 1972
and 1984. Recent redevelopment of the computer system at ONS,
however, means that vital status can now effectively be confirmed for
all individuals registered with cancer in England and Wales from
1971–90, and this initial report will, therefore, be followed by an
analysis of the entire ONS database for this period.
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Figure 1 Relative survival with acute lymphatic leukaemia in patients aged
0–14 diagnosed 1972–84
Figure 2 Relative survival with acute myeloid leukaemia in patients aged
0–14 diagnosed 1972–84
Figure 3 Relative survival with acute lymphatic leukaemia in patients aged
15–34 diagnosed 1972–84Estimating relative survival in cancer patients 21
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As outlined in Materials and methods, time since diagnosis was
divided up into yearly intervals; for each of these intervals,
person–years and expected numbers of deaths were calculated
using published death rates for England and Wales from all causes
except that under study. All calculations were carried out using the
PERSON–YEARS program (Coleman et al, 1986). For the purposes of
these analyses, follow-up was censored at 1 January 1990 and
cancers which were registered at the time of death were excluded.
Results are shown separately for five selected sites. For each
cancer, a plot of the cumulative relative survival rate (equation 4)
was plotted against time since diagnosis. Because we are particu-
larly interested in trends in survival over calendar period, relative
survival curves are calculated separately for individuals diagnosed
in periods 1972–75, 1976–78, 1979–81 and 1982–84. Figures 1–7
show plots of the cumulative relative survival up to 10 years after
diagnosis for selected primary sites and age groups according to
calendar period of diagnosis. Table 1 summarizes these results and
gives the total number of registrations available for analysis in
each case.
The results show that for some, but not all, of these cancers,
survival for individuals aged 15–34 at diagnosis has improved
substantially between 1972 and 1984. The most dramatic increases
in survival shown here are for leukaemia. Because leukaemia is
the most common childhood cancer, survival with acute lymphatic
leukaemia (ALL) and with acute myeloid leukaemia (AML) is
given both for children diagnosed under the age of 15 (Figures 1
and 2) and for adults aged 15–34 at diagnosis (Figures 3 and 4).
The results for childhood leukaemia show that 5-year relative
survival rates with AML increased from 9% in 1972–75 to 34% in
1982–84, whereas the rates for ALL increased from 45% to 74%
over the same period. The results for adult leukaemias also show
marked improvements in survival. In particular, 5-year relative
survival rates for AML diagnosed at ages 15–34 rose from 6% in
1972–75 to 31% in 1982–84, whereas figures for ALL showed an
increase from 22% to 44% over the same period. The results for
testicular cancer (Figure 5) also show a gradual and significant
increase in survival over this period, with 5-year relative survival
rising from 65% in 1972–75 to 89% in 1982–84. Patients with
Hodgkin’s disease, aged 15–34 at diagnosis, showed some
improvement in survival between 1972–84 (Figure 6) with 5-year
relative survival increasing from 76% in 1972–75 to 87% in
1982–84. By comparison, survival with breast cancer among
cancer patients aged 15–34 (Figure 7) showed relatively little
change over this period.
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Figure 4 Relative survival with acute myeloid leukaemia in patients aged
15–34 diagnosed 1972–84
Figure 7 Relative survival with breast cancer in patients aged 15–34
diagnosed 1972–84
Figure 5 Relative survival with testicular cancer in patients aged 15–34
diagnosed 1972–84
Figure 6 Relative survival with Hodgkin’s disease in patients aged 15–34
diagnosed 1972–8422 GK Reeves et al
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DISCUSSION
The main purpose of this paper is to illustrate a simple method of
calculating relative survival based on routine data. Nevertheless, it
highlights some interesting trends in the survival of young people
diagnosed with certain cancers. Moreover, the patterns of survival
observed are reassuringly in line with what is known about recent
advances in the treatment of those cancers. For example, examina-
tion of the relative survival rates for testicular cancer by individual
year between 1972 and 1984 suggest that the biggest increases
occurred during the periods 1976–77 and 1979–80 (data not
shown). This is likely to be due to the introduction of cisplatin-
based chemotherapy, which was first used around 1976 before the
commencement of widespread use in 1979 (Edmiston and Stewart,
1993). With regard to acute lymphatic leukaemia and acute
myeloid leukaemia, the results shown here for children diagnosed
under the age of 15 show similar patterns to those found by Stiller
and Bunch (1990), who examined trends in survival with child-
hood cancers in England and Wales over the period 1971–85. The
results also suggest that, to a certain extent, these improvements
extend to young adults diagnosed at ages 15–34 and this finding is
broadly in line with data on adolescent patients from Sweden
(Adami et al, 1992).
One question which is often of interest in analyses of survival
patterns in cancer patients is whether or not patients can ever be
assumed to be effectively ‘cured’ of a particular cancer. One defin-
ition of curability, though not necessarily equivalent to a clinical
definition, is when a patient assumes the same mortality rate as
that of the general population. In such cases, the cumulative rela-
tive survival curve would be expected to level off after a given
length of time. For some of the cancers shown here, such as
leukaemia and testicular cancer, it is clear that this ultimately
appears to be the case. For example, Figure 5 suggests that not
only do as many as 89% of all testicular cancer patients diagnosed
in 1982–84 survive beyond 5 years, but that those that do are no
longer at any increased risk of death compared with the general
population. For cancers such as breast cancer, in which there is no
obvious levelling off in the cumulative relative survival rate before
10 years after diagnosis (Figure 7), the picture is less clear, and this
has long been an area for discussion in the literature (Brinkley and
Haybrittle, 1975; Duncan and Kerr, 1976; Langlands, 1995). In
such cases, it is important to extend the estimates of cumulative
relative survival to assess whether a certain proportion of patients
ever reach a point at which they are no longer at an increased risk
of death relative to the general population.
In this particular example, in which the data consist of relatively
young patients, it is unlikely that the relative survival rates would
have differed substantially from crude survival rates. There would,
however, almost certainly be important differences if assessing
trends in survival among older patients among whom a substantial
proportion of the observed deaths would be likely to be due to
other causes. Furthermore, although we have introduced the notion
of relative survival in the context of analyses in which the cause of
death is unavailable, there are arguments for applying this method
to data in which cause of death can be ascertained from death certi-
fication data. Several authors have commented on the fact that
even when cause of death has been routinely recorded, it is often
difficult to determine whether a patient’s death was due directly or
indirectly to their cancer and in those cases relative survival may
provide a more objective means of removing the effect of
mortality from other causes (Berkson and Gage, 1950).
In summary, this report discusses some of the issues
surrounding the analysis of trends in survival based on routinely
collected cancer registration data, and illustrates a relatively
simple but robust method of calculating an estimate of relative
survival which is suitable for use with large data sets. The exam-
ples presented here also highlight some very promising trends in
the survival of young adults with certain cancers, particularly
those with leukaemia and testicular cancer.
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